Daniel S. Grau
Vorstandsvorsitzender bei Theriana Pharmaceuticals, Inc.
Profil
Daniel S.
Grau was the founder of Sojournix, Inc. (founded in 2016) where he held the title of President, Chief Executive Officer & Director.
He is currently the President, CEO, Secretary, Treasurer & Director at Theriana Pharmaceuticals, Inc., Chairman at Lusaris Therapeutics, Inc., and Director at AbCellera Boston, Inc. (since 2019).
In his former positions, he served as Vice Chairman & Chief Executive Officer at Cortria Corp., President & Chief Executive Officer at Avilar Therapeutics, Inc., and Director at Concert Pharmaceuticals, Inc. He was also a Director at Therapeutics Acquisition Corp.
and President at Nxera Pharma UK Ltd.
Additionally, he worked as the Chief Operating Officer at CombinatoRx, Inc. from 2001 to 2008 and as a Management Consultant at Pharmacia Corp.
Mr. Grau completed his undergraduate degree at Davidson College and his graduate degree at Yale University.
Aktive Positionen von Daniel S. Grau
| Unternehmen | Position | Beginn |
|---|---|---|
Theriana Pharmaceuticals, Inc.
 Theriana Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Theriana Pharmaceuticals, Inc. provides pharmaceutical services. The company was founded in 2017 and is headquartered in Waltham, MA. | Vorstandsvorsitzender | - |
AbCellera Boston, Inc.
 AbCellera Boston, Inc. BiotechnologyHealth Technology AbCellera Boston, Inc. produces vaccines for plant, animal, and human diseases. It focuses on the discovery of novel therapeutics for autoimmune disease and pain. The company was founded by Theodore G. Clark in 2004 and is headquartered in Arlington, MA. | Direktor/Vorstandsmitglied | 02.05.2019 |
Lusaris Therapeutics, Inc.
 Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin. | Vorsitzender | - |
Ehemalige bekannte Positionen von Daniel S. Grau
| Unternehmen | Position | Ende |
|---|---|---|
CombinatoRx, Inc.
 CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Geschäftsführer | 06.05.2008 |
Avilar Therapeutics, Inc.
 Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Vorstandsvorsitzender | - |
| THES ACQU | Direktor/Vorstandsmitglied | - |
Sojournix, Inc.
 Sojournix, Inc. BiotechnologyHealth Technology Sojournix, Inc. operates in the healthcare industry focusing on biotechnology business. It develops medicines for women’s health and endocrine disorders. The company was founded by Scott L. Rakestraw and Daniel Grau in 2016 and is headquartered in Waltham, MA. | Gründer | - |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Präsident | - |
Ausbildung von Daniel S. Grau
| Davidson College | Undergraduate Degree |
| Yale University | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
CombinatoRx, Inc.
CombinatoRx, Inc. Pharmaceuticals: OtherHealth Technology CombinatoRx, Inc. develops new medicines built from synergistic combinations of approved drugs. The company develops biopharmaceutical products. It conducts clinical trials and research programs. The company was founded by Alexis Borisy, Brent R. Stockwell, Michael A. Foley, Curtis T. Keith and Jacob D. Goldfield in 2000 and is headquartered in Cambridge, MA | Health Technology |
Concert Pharmaceuticals, Inc.
 Concert Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA. | Health Technology |
Cortria Corp.
 Cortria Corp. Pharmaceuticals: MajorHealth Technology Cortria Corp. operates as a clinical-stage pharmaceutical company that focuses on developing medicines to fight cardiovascular disease. Its product is used for the treatment of dyslipidemia, an atherogenic disorder characterized by abnormal lipid levels in the bloodstream. The company was founded in August 2005 and is headquartered in Needham, MA. | Health Technology |
AbCellera Boston, Inc.
AbCellera Boston, Inc. BiotechnologyHealth Technology AbCellera Boston, Inc. produces vaccines for plant, animal, and human diseases. It focuses on the discovery of novel therapeutics for autoimmune disease and pain. The company was founded by Theodore G. Clark in 2004 and is headquartered in Arlington, MA. | Health Technology |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Health Technology |
Sojournix, Inc.
Sojournix, Inc. BiotechnologyHealth Technology Sojournix, Inc. operates in the healthcare industry focusing on biotechnology business. It develops medicines for women’s health and endocrine disorders. The company was founded by Scott L. Rakestraw and Daniel Grau in 2016 and is headquartered in Waltham, MA. | Health Technology |
Theriana Pharmaceuticals, Inc.
Theriana Pharmaceuticals, Inc. Drugstore ChainsRetail Trade Theriana Pharmaceuticals, Inc. provides pharmaceutical services. The company was founded in 2017 and is headquartered in Waltham, MA. | Retail Trade |
Therapeutics Acquisition Corp.
 Therapeutics Acquisition Corp. Financial ConglomeratesFinance Therapeutics Acquisition Corp. is a blank check company with a purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Peter Kolchinsky and Matthew Hammond on April 15, 2020 and is headquartered in Boston, MA. | Finance |
Avilar Therapeutics, Inc.
Avilar Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Avilar Therapeutics is an American biopharmaceutical company that specializes in the discovery and development of extracellular protein degraders. The company is based in an undisclosed location. The company has developed a proprietary discovery platform that includes novel, high-affinity, small molecule asgpr ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of atac mediated endocytosis and degradation. Avilar is developing atacs, a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. The company is leveraging their atac platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. The company was founded by Nathaniel Brooks Horwitz and Jamie Kasuboski. The CEO is Daniel S. Grau. | Commercial Services |
Lusaris Therapeutics, Inc.
Lusaris Therapeutics, Inc. BiotechnologyHealth Technology Lusaris Therapeutics, Inc. is a biotechnology company that focuses on developing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. The company is based in Boston, MA. The company's lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic, which is being developed to treat treatment-resistant depression and other neuropsychiatric conditions. The company's pipeline also includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions, including migraine and cluster headache. The CEO of the company is Andrew D. Levin. | Health Technology |
